Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aee-788. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 11/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 3/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | BCR | P11274 | 1/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 1/20 | 1.00 |
| ▸ | WEE1 | P30291 | 1/20 | 1.00 |
| ▸ | ABL2 | P42684 | 1/20 | 1.00 |
| ▸ | NEK3 | P51956 | 1/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 1/20 | 1.00 |
| ▸ | LIMK2 | P53671 | 1/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 1/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 1/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aee-788 SCHEMBL29478848 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL613755 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL1738023 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL29389001 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL613756 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL10259799 | 0.99 | EGFR (0.98) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL93737 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL93738 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL4767093 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL27585261 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240392315-A1 | COMPOSITION FOR CELL ADDITION | AGC Inc. (JP) | 2024-11-28 | — | — | US | disclosed |
| EP-4424705-A1 | COMPOSITION FOR CELL ADDITION | AGC INC. (JP) | 2024-09-04 | — | — | EP | disclosed |
| CN-118369582-A | Liquid composition containing lung surfactant protein, immunoassay kit containing same, and method for improving storage stability of lung surfactant protein | 积水医疗株式会社 | 2024-07-19 | — | — | CN | disclosed |
| US-20220347112-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. | 2022-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347112-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | TERT, PLTP, PCTP | EGFR 2893/4885KDR 3824/4885ERBB2 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.